Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
03 mars 2023 16h05 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the completion of its previously announced underwritten public offering of 9,703,750 shares of...
Travere Therapeutics Announces Proposed Public Offering of Common Stock
27 févr. 2023 16h01 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and...
Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
23 févr. 2023 16h01 HE
|
Travere Therapeutics, Inc.
Recently received U.S. FDA accelerated approval of FILSPARI™ (sparsentan), the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy (IgAN) European...
Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
16 févr. 2023 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2022 financial results on Thursday, February 23,...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 févr. 2023 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2023, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics to Present at Upcoming Investor Conferences
08 févr. 2023 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences: SVB Securities...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 janv. 2023 19h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on January 10, 2023, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics Provides Corporate Update and 2023 Outlook
09 janv. 2023 07h00 HE
|
Travere Therapeutics, Inc.
Company well-positioned for potential FDA Subpart H approval and commercial launch of sparsentan for IgA nephropathy (IgAN) in 1Q23, followed by potential EMA approval in second half of 2023 ...
Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present a corporate overview...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 déc. 2022 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on December 10, 2022, the Compensation Committee of its Board of Directors granted...